Ra Capital Management, L.P. Avadel Pharmaceuticals PLC Call Options Transaction History
Ra Capital Management, L.P.
- $4.58 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AVDL
# of Institutions
7Shares Held
738KCall Options Held
25KPut Options Held
0-
Knoll Capital Management, LLC Miami, FL600KShares$8.67 Million3.61% of portfolio
-
Schulhoff & CO Inc138KShares$1.99 Million0.58% of portfolio
-
American Portfolios Advisors Holbrook, NY500Shares$7,2250.0% of portfolio
-
American Research & Management Co.100Shares$1,4450.0% of portfolio
-
Exane Derivatives33Shares$4760.0% of portfolio
About AVADEL PHARMACEUTICALS PLC
- Ticker AVDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 60,581,300
- Market Cap $875M
- Description
- Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...